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The present study was designed to evaluate the behavi-
oral and neurochemical profiles of clozapine and risperi-
done in rats in a dose-dependent manner. Animals in-
jected intraperitoneally (i.p.) with clozapine (2.5, 5.0 and
10.0 mg kg–1) or risperidone (1.0, 2.5 and 5.0 mg kg–1) were
sacrificed 1 h later to collect brain samples. Hypolocomo-
tive effects (home cage activity and catalepsy) were suc-
cessively monitored in each animal after the drug or sa-
line administration. Both drugs significantly (p < 0.01)
decreased locomotor activity at high doses and in a do-
se-dependent manner. Maximum (100 %) cataleptic po-
tential was achieved at a high dose (5.0 mg kg–1) of ris-
peridone. Neurochemical estimations were carried out
by HPLC with electrochemical detection. Both drugs, at
all doses, significantly (p < 0.01) increased the concentra-
tion of homovanillic acid (HVA), a metabolite of dopa-
mine (DA), in the striatum. Dihydroxyphenylacetic acid
(DOPAC) levels increased in the striatum and decreased
in the rest of the brain, particularly in clozapine-injected
rats. 5-Hydroxyindoleacetic acid (5-HIAA), the predomi-
nant metabolite of serotonin, significantly (p < 0.01) de-
creased in the striatum. 5-Hydroxytryptamine (5-HT)
was significantly (p < 0.01) increased by risperidone and
decreased by clozapine in the rest of the brain. Striatal
tryptophan (TRP) was significantly (p < 0.01) decreased
by risperidone and increased in the rest of the brain. The
striatal HVA/DA ratio increased and the 5-HT turnover
rate remained unchanged in the rest of the brain. Results
suggest that the affinity of the two drugs towards
D2/5-HT1A receptors interaction is involved in lower in-
cidence of extrapyramidal side effects. Role of 5-HT1A re-
ceptors in the treatment of schizophrenia is discussed.
Keywords: atypical antipsychotics, dopamine D2 receptors,
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Schizophrenia is one of the most severe and debilitating psychiatric diseases. The
introduction of antipsychotic drugs was indisputably a great advance in the pharmaco-
therapy of mental disorders (1). Typical and atypical neuroleptics have been differenti-
ated on the basis of their ability to enhance dopamine (DA) release in different meso-
-telencephalic DA projections. Atypicality has been ascribed to serotonin (5-hydroxytry-
ptamine, 5-HT) and DA (5-HT2/D2) antagonism that may be involved in the antipsychotic
effect (2). A majority of schizophrenic patients respond to classical neuroleptic drugs,
which are believed to act largely via the blockade of dopamine D2 receptors in limbic
structures (3). Moreover, the concomitant blockade of D2 receptors in the basal ganglia
has been associated with the appearance of extrapyramidal side effects (EPS) (2, 3). The
typical effect of administering a DA receptor antagonist is suppression of spontaneous
locomotor behavior and elicitation of a state known as catalepsy (4). Selective antago-
nists of DA-D2 receptors can elicit catalepsy (3, 4). Moreover, receptors on the striatum
appear to play an important role in the elicitation of catalepsy (4). The dopamine system
has traditionally been considered fundamental to the control of motor activity (5). With
respect to the anatomical site of action, a view has developed that the striatum is in-
volved in the control of extrapyramidal motor functions. A survey of clinical literature
shows that haloperidol is very likely to produce EPS, clozapine is relatively unlikely and
risperidone is somewhat mild in terms of the production of these effects (6). In compari-
son with classical neuroleptics, atypical antipsychotic drugs such as, for example,
clozapine and risperidone have been found to possess improved efficacy against nega-
tive symptomatology and to cause reduced incidence of EPS in clinically effective doses
(5, 6). The present work was undertaken in an attempt to gain further insights into the
mechanisms of action of atypical antipsychotic drugs.
Clozapine, the first atypical antipsychotic, has been reported to be effective in ap-
proximately one third or two thirds of patients with a treatment resistant disease (7). Ob-
viously, a goal of the current neuroleptic research is to develop antipsychotic compo-
unds with low incidence of EPS and agranulocytosis. One of the approaches in this con-
text has been to determine neurochemical/pharmacological correlates of clozapine and
other atypical neuroleptics. A notable feature of the pharmacology of clozapine is its af-
finity for serotonergic receptors, particularly 5-HT2A, 5-HT2C and 5-HT1A receptors (8).
Risperidone, a benzisoxazol derivative, provided further evidence that potent 5HT2A an-
tagonism combined with milder D2 antagonism (9) resulted in significantly improved
clinical properties (10). Indeed, in addition to successful treatment of the positive symp-
toms, risperidone markedly improved the negative symptoms of schizophrenia with a
low liability of EPS (2, 3, 11). Other authors have shown that the main reason for the de-
velopment of atypical antipsychotics was to provide an antipsychotics treatment option
that was free of EPS and, further, to reduce the risk of tardive dyskinesia (12).
The primary objective of the present study was, therefore, to compare the effects of
various doses of clozapine and risperidone on extrapyramidal motor functions and on
brain serotonin and DA metabolism. Homovanillic acid (HVA) and dihydroxyphenyl
acetic acid (DOPAC) are the predominant metabolites of DA, while 5-hydroxyindole
acetic acid (5-HIAA) is the predominant metabolite of 5-HT. Hence, in the present study,
the effects of clozapine and risperidone on HVA/DA and 5-HIAA/5-HT ratios are also
compared.
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EXPERIMENTAL
Animals
The protocol for experimentation was approved and performed in strict accordance
with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Ani-
mal Resources on Life Sciences, US National Research Council, 1996) and the Institutio-
nal Animal Ethics Committee (University of Karachi, Pakistan). The guidelines of IAEC,
the governing body for animal experimentations in Pakistan, were strictly adhered to
during the whole animal experimentation protocol. Locally bred male albino Wistar rats
with an average body mass of 180 ± 20 g (from Agha Khan University, Karachi, Pakistan)
were fed a standard diet and allowed water ad libitum. The animals were group-housed
(two rats per cage) in an environmentally controlled room (ambient temperature 24 ± 2
°C and relative humidity 55 ± 5 %) on a 12:12 h light/dark cycle (lights on at 7:00 a.m.).
A 5-day acclimatization period was allowed before animals were used in experiments.
After this period, and 24 h before the behavioral tests, the animals were individually hou-
sed in an environmentally controlled test room in transparent Perspex cages (dimensions
26 ´ 26 ´ 26 cm) in order to avoid any false effect.
Drugs and injections
Clozapine (Sigma, Germany) was dissolved in a minimal volume of 0.1 mol L–1 ace-
tic acid and pH was adjusted to 6.5 by NaOH and diluted with physiological saline (0.9 %
NaCl) to desired concentrations of 2.5, 5.0 and 10.0 mg mL–1 and injected in volumes of
1.0 mL kg–1 body mass. Risperidone (Janssen, USA) was dissolved in 0.4 mol L–1 tartaric
acid and pH was adjusted to 6.5 by NaOH and diluted with saline to the desired concen-
trations of 1.0, 2.5 and 5.0 mg mL–1 and injected in volumes of 1.0 mL kg–1 body mass.
Control animals received equal volum of vehicle (0.1 mol L–1 acetic acid, 0.1 mol L–1
NaOH and/ or 0.4 mol L–1 tartaric acid and saline in the ratio 1:1:8). The animals were
injected following a balanced pattern between 10:00 and 11:00 h and the route of admin-
istration used for vehicle and drugs was intraperitoneal (i.p.). Motor activity was moni-
tored for 10 min starting 10 min after injections. Catalepsy effects of the drugs were
scored for a cut-off time of 3 min starting 30 min post injections and animals were killed
to collect brain samples 1 h after injections. All the reagents used during the study were
of analytical grade.
Behavioral study
Dose-related motor effects of clozapine and risperidone. – Motor-related effects of the
drugs were monitored in Perspex activity cages. Animals were transferred to Perspex
activity cages with saw dust-covered floor 15 min before injecting the saline or drug. Ex-
periment was conducted in a separate quiet room. Motor activity in the activity box was
monitored under white light as the number of cage crossings per 10 min starting 10 min
post injections (13).
Dose-related cataleptic effects of clozapine and risperidone. – Catalepsy, defined as the ac-
ceptance and retention of abnormal posture, was measured by means of a bar test. Bar
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test determinations were carried out by gently removing rats from their home cages and
placing their forepaws over a horizontal bar, fixed at a height of 10 cm, with heads of ani-
mals upwards on an inclined surface at an angle of 60° with the hind limbs abducted
(14). The length of time during which the animal retained this position was recorded by
measuring the time from the placement of the rat until removal of one of its forepaws.
The animal to be tested was placed on an inclined surface (26 ´ 40 cm, 60° inclination)
for a cut-off time of 3 min (180 s). A control rat changes its position immediately on the
inclination. Time (in s) during which drug or saline injected animals remained immobile
on the inclination was monitored. Animals not moving on the inclined surface up to 3
min were put back in their cages. To better measure the catalepsy (avoiding false results),
the animals were tested twice at each time interval and only the longest duration of time
was recorded. The cataleptic score was calculated as [latency of movement (s)/cut-off
time (180 s)] 100.
Neurochemical analysis
Dissection of the striatum. – Saline, clozapine or risperidone injected animals were
killed 1 h post injections. The dissection procedure was essentially the same as described
elsewhere (15, 16). A fresh brain was dipped into ice-cold saline and placed with its ven-
tral side up in the molded cavity of a brain slicer. Fine fishing line wire was inserted into
the slots of the slicer to give slices of 2 mm thickness. The slice containing the striatum
was transferred to a slide kept on ice. Punches of 2.5 mm diameter were made bilaterally
in the striatum to collect the brain region. The striatum, also known as striate body, neo-
striatum or striate nucleus, is a subcortical (i.e., inside, rather than outside) part of the
telencephalon/cerebrum. It is the major input station of the basal ganglia system. In pri-
mates (including humans), the striatum is divided by a white matter tract called the in-
ternal capsule into two sectors, called the caudate nucleus and putamen. The rest of the
brain was also stored for the biogenic amine assay. The samples were stored at –70 °C
for the estimation of DOPAC, DA, HVA, 5-HIAA and 5-HT by high performance liquid
chromatography with electrochemical detection (HPLC-EC) (17, 18).
HPLC-EC analysis. – Biogenic amines and their major metabolites were extracted
with 150 mL of perchloric acid (70 %) from brain tissue punches (< 250 mg) using a simple
one-step sample preparation method (19). A 5-mm (particle size) ODS column (4.0 mm
i.d. and 250 mm length) was used. Mobile phase comprising methanol (14 %), octyl so-
dium sulphate (0.023 %) and EDTA (0.0035 %) in 0.1 mol L–1 phosphate buffer of pH 2.9
was passed through the column at a constant flow rate (1.0 mL min–1) with the help of a
Waters 510 HPLC pump (Waters Corporation, USA). Electrochemical detection was achie-
ved on a Shimadzu L-EC 6A detector (Shimadzu, Japan) at an operating potential of 0.8 V.
Tryptophan was determined in a separate run at an operating potential of 1.0 V (17–19).
This method was employed to study the effects of intraperitoneal administration of
clozapine and risperidone on biogenic amines in a number of discrete rat brain regions.
Statistical analysis
All behavioral and neurochemical parameters were calculated for each animal, and
the data was presented as arithmetic mean ± standard deviation. Statistical analysis was
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performed using one-way ANOVA (analysis of variance) and post-hoc comparison was
made by the Newman-Keuls test.
RESULTS AND DISCUSSION
The results of the experiments examining the dose-related effects of clozapine and
risperidone on behavioral deficits are shown in Fig. 1. ANOVA showed significant ef-
fects of clozapine (2.5, 5.0 and 10.0 mg kg–1) and risperidone (1.0, 2.5 and 5.0 mg kg–1) on
motor activity (p < 0.01) and on catalepsy (p < 0.01). Our data showed that all the doses
of clozapine and risperidone decreased motor activity in a dose-dependent manner (Fig.
1). Both drugs were found cataleptogenic only at high doses. However, hypolocomotive
effects of both drugs were found 100 % only at high doses of clozapine (5.0 mg kg–1) and
risperidone (10.0 mg kg–1). Post-hoc analysis showed that maximum (100 %) catalepsy
occurred only at a dose of 10.0 mg kg–1 clozapine and 5.0 mg kg–1 of risperidone when
compared with the respective saline-treated rats. The most important finding of the pre-
sent study is that clozapine did not decrease locomotor activity at a dose of 2.5 mg kg–1.
No catalepsy was observed at doses of 2.5 mg kg–1 and 5.0 mg kg–1 clozapine. Akinesia
and 62 % catalepsy were produced only at the cataleptogenic dose of 10.0 mg kg–1 of
clozapine.
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Fig. 1. Dose-related effects of clozapine and risperidone on motor activity and cataleptic potential.
Values are mean ± SD (n = 12). Significant differences by the Newman-Keuls test: *p < 0.05, **p < 0.01
compared to respective saline-treated rats following one-way ANOVA.
An important finding of the present study is that acute administration of
risperidone relatively uniformly increases DA release and metabolism in the striatum re-
gion of rat brain. The proposed mechanism of HVA changes involves acute blockade of
pre- and postsynaptic D2 receptors (3, 20). It has been reported that only the postsynap-
tic DA-D2 receptors are blocked by antipsychotics drugs in direct relation to their clini-
cal antipsychotic potencies. No drug has been identified with antipsychotic action with-
out a significant affinity for D2 receptors. The present study, therefore, implies that the
blockade of the DA-D2 receptors and responsiveness of 5-HT1A receptors produce anti-
schizophrenic effects. The apparently low occupancy of D2 receptors by clozapine sug-
gests that D2 is not the major antipsychotics target; in addition, also atypical antipsy-
chotics have affinities for 5-HT receptors and may by involved in their ability to produce
fewer EPS (20). In addition, it is possible that the relative lack of EPS motor effects with
clozapine and risperidone administration in the present study could be related to the
two-way interaction between DA and 5-HT receptors. Fig. 2 shows the effects of various
doses of clozapine and risperidone on the levels of dopamine (DA), metabolites dihydro-
xyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and 5-hydroxyindoleacetic
acid (5-HIAA) in the striatum. ANOVA showed significant effects of clozapine on the
levels of DA (p < 0.01), HVA (p < 0.01), DOPAC (p < 0.05) and 5-HIAA (p < 0.05). Effects
of risperidone were also significant for HVA (p < 0.05). Effects of risperidone on DA,
DOPAC and 5-HIAA were not significant. Comparison with post-hoc analysis showed
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Fig. 2. Dose-related effects of clozapine and risperidone on the levels of DOPAC, DA, HVA and
5-HIAA in the rat striatum. Values are mean ± SD (n = 12). Significant differences by Newman-Keuls
test: *p < 0.05, **p < 0.01 compared to respective saline-treated rats following one-way ANOVA.
that the effects of risperidone on DOPAC changes were not significant when compared
to the respective controls. Rats injected with 2.5 mg kg–1 and 5.0 mg kg–1 risperidone ex-
hibited pronounced 2–3 fold increases in HVA concentration and these increases were
also comparable when measured against saline-treated animals. HVA levels were also
increased following the administration of clozapine and reached a maximum at a dose
of 5.0 mg kg–1. Maximum increases of HVA were higher in risperidone than clozapine
injected animals. It is now generally agreed that the clinical response to neuroleptics is
associated with an increase in HVA concentration (21) and the observed increases of
HVA, particularly in the striatum (Fig. 2), are taken as distinguished clinical features of
both drugs in the treatment of psychosis. The concentration of DOPAC also increased
following the administration of clozapine at doses of 2.5 and 5.0 mg kg–1. DOPAC levels
did not increase at the cataleptogenic dose of 10.0 mg kg–1 of clozapine. 5-HIAA levels
increased following the administration of a high dose of risperidone but these increases
were insignificant. Conversely, clozapine administration did decrease 5-HIAA concen-
tration only at the high dose of 10.0 mg kg–1. The decreases by clozapine that were not
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Fig. 3. Dose-related effects of clozapine and risperidone on the levels of DOPAC, DA, HVA, 5-HIAA
and 5-HT in the rest of the brain. Values are mean ± SD (n = 12). Significant differences by the Newman-
-Keuls test: *p < 0.05, **p < 0.01 compared to respective saline-treated rats following one-way ANOVA.
significant at doses of 2.5 mg kg–1 and 5.0 mg kg–1 were significant (p < 0.01) at the
cataleptogenic dose of 10.0 mg kg–1.
Data analyzed by ANOVA regarding the levels of DOPAC, DA, HVA, 5-HIAA and
5-HT in the rest of the brain are illustrated in Fig. 3. Significant effect of clozapine on
DOPAC (p < 0.01), DA (p < 0.01), HVA (p < 0.01), 5-HT (p < 0.01) and 5-HIAA (p < 0.05)
concentrations was evident. Effects of risperidone were only significant for HVA (p < 0.01),
5-HIAA (p < 0.01) and 5-HT (p < 0.01) and not significant for DOPAC and DA. Post-hoc
comparison by the Newman-Keuls test showed that risperidone significantly increased
HVA levels in a dose-dependent manner and all the increases were comparable when
measured against the respective saline-treated group of rats. Conversely, clozapine sig-
nificantly decreased HVA concentration only at a dose of 2.5 mg kg–1. The decreases
were not significant at higher doses of clozapine (5.0 and 10.0 mg kg–1). Concentration
of DOPAC also decreased following the administration of clozapine at doses of 2.5 and
5.0 mg kg–1 but not at the cataleptogenic dose of 10.0 mg kg–1. Concentration of 5-HIAA
and 5-HT increased following the administration of risperidone at doses of 1.0 and 5.0
mg kg–1 but not at dose of 2.5 mg kg–1. Clozapine, at all doses, significantly decreased
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Fig. 4. Dose-related effects of clozapine and risperidone on the levels of tryptophan, HVA/DA and
5-HIAA/5-HT ratios in the striatum and the rest of the brain. Values are mean ± SD (n = 12). Signifi-
cant differences by the Newman-Keuls test: *p < 0.05, **p < 0.01 compared to respective saline-trea-
ted rats following one-way ANOVA.
the levels of 5-HIAA in the striatum and the rest of the brain. 5-HT levels were also sig-
nificantly decreased at doses of 2.5 and 10.0 mg kg–1 in the rest of the brain (Fig. 3).
Serotonergic mechanisms are also known to influence neuroleptic-induced catale-
psy (21, 22). The serotonergic effects of clozapine have been also emphasized as possibly
being related to the unique clinical characteristics of clozapine (22, 23), and it was re-
cently suggested that the 5-HT2A/D2 binding ratio could be used to distinguish between
typical and atypical antipsychotics. A decrease in 5-HT metabolism by clozapine is ex-
plicable in terms of the drug moderate affinity for 5-HT1A receptors. Tissue measurements
of regional DA and 5-HT metabolism in the rat brain have indicated that risperidone af-
fects the DA turnover in both mesolimbic and nigrostriatal terminal regions and, to
some extent, also 5-HT metabolism in these target areas (23–25). The dose-related effects
of clozapine and risperidone on the levels of tryptophan and the ratio HVA/DA and
5-HIAA/5-HT in the striatum and the rest of the brain are depicted in Fig. 4. ANOVA
performed on striatal data showed a significant effect of risperidone on TRP (p > 0.05)
and insignificant for HVA/DA (p > 0.05) ratio. Effects of clozapine were insignificant for
TRP and significant for HVA/DA ratio. Data on the rest of the brain showed an insig-
nificant effect of risperidone on TRP (p > 0.05). Post-hoc analysis showed that the ratio
HVA/DA decreased in the striatum of clozapine injected rats compared to saline-treated
rats and the decreases were not significant at doses of 2.5 and 5.0 mg kg–1 but were sig-
nificant at the dose of 10.0 mg kg–1. Conversely, the 5-HT turnover rate remained unal-
tered following the administration of clozapine. Administration of risperidone signifi-
cantly increased the HVA/DA ratio at a low dose (1.0 mg kg–1). ANOVA performed on
the data of the rest of the brain showed insignificant effects of clozapine and risperidone
on TRP and the 5-HIAA/5-HT ratio. Post-hoc test showed non-significant decreases at
the 5-HIAA/5-HT ratio following the administration of clozapine and risperidone com-
pared to saline-treated rats. Results revealed that levels of 5-HIAA were significantly in-
creased at low (1.0 mg kg–1) and high (5.0 mg kg–1) doses of risperidone in the rest of the
brain when compared to saline-treated rats (Fig. 3). In contrast, clozapine administration
decreased the 5-HT turnover rate in the rest of the brain at doses of 5.0 and 10.0 mg kg–1.
Comparison of the effects of these two drugs shows that increases in HVA concentration
in the striatum and decreases in 5-HT in the rest of the brain may be taken as a neuro-
chemical profile of atypical, clozapine-like, activity.
CONCLUSIONS
In conclusion, the present study shows that both clozapine and risperidone increase
the brain regional DA turnover in a comparable manner. The results also suggest that
administration of atypical antipsychotics at low doses produces fewer EPS in terms of
lower hypolocomotive effects in rats in both familiar and novel environments. This is ex-
plainable since drugs that tend towards serotonin receptors are known to be involved in
lower EPS production. The effects of both drugs on 5-HT metabolism are quantitatively
similar. Both drugs decrease the 5-HT metabolism in the rat brain striatum. Although
other atypical neuroleptics could produce different neurochemical effects, depending
upon their activity towards different types of DA and serotonin receptors, an increase in
the DA:serotonin metabolite ratio, particularly in the striatum, may be taken as a neuro-
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chemical profile of atypical, clozapine-like, activity. These results therefore suggest an
important role of 5-HT in the treatment of resistant schizophrenia and lower incidence
of EPS. Future work will identify better treatments for these symptoms, as well as new
antipsychotic agents that do not cause EPS.
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S A @ E T A K
O dozi ovisni u~inci klozapina i risperidona na metabolizam serotonina i
dopamina u pojedinim podru~jima mozga i na ekstrapiramidalne nuspojave u
{takora
FARHAT BATOOL, AMBREEN HASNAT, MUHAMMAD ABDUL HALEEM i DARAKHSHAN JABEEN HALEEM
Cilj rada bio je procjena pona{anja i neurokemijskog profila klozapina i risperidona
u ovisnosti o dozi nakon primjene na {takorima. Pokusnim `ivotinjama intraperitonealno
je injiciran klozapin (2,5, 5,0 i 10,0 mg kg1) ili risperidon (1,0, 2,5 i 5,0 mg kg1). Nakon
jednog sata `ivotinje su `rtvovane i uzeti su uzorci mozga. Nakon primjene lijeka ili fi-
ziolo{ke otopine pra}eni su hipolokomotori~ki u~inci (aktivnost u kavezu i katalepsija).
Oba lijeka su pri visokim dozama zna~ajno smanjila (p < 0,01) lokomotori~ku aktivnost,
a smanjenje je ovisilo o dozi. Maksimalni (100 %) katalepti~ki u~inak postignut je viso-
kom dozom risperidona (5,0 mg kg1). Neurokemijske procjene provedene su pomo}u
HPLC s elektrokemijskom detekcijom. Oba lijeka su pri svim dozama zna~ajno (p < 0,01)
pove}ala koncentraciju homovanilinske kiseline (HVA), metabolita dopamina (DA), u stria-
tumu. Koncentracija dihidroksifeniloctene kiseline (DOPAC) u striatumu bila je pove}a-
na, a u ostatku mozga smanjena, posebno nakon primjene klozapina. Koncentracija 5-hi-
droksiindol octene kiseline (5-HIAA), najva`nijeg metabolita serotonina, zna~ajno (p <
0,01) se smanjila u striatumu. 5-Hidroksitriptamin (5-HT) zna~ajno se pove}ao (p < 0,01)
nakon risperidona, a smanjio nakon klozapina u ostalim dijelovima mozga. Risperidon
je zna~ajno smanjio triptofan (TRP) u striatumu (p < 0,01), a pove}ao njegovu koncen-
traciju u ostalim dijelovima mozga. Tako|er je pove}ao omjer HVA/DA u striatumu, dok
je metabolizam 5-HT ostao nepromijenjen u ostalim dijelovima mozga. Rezultati upu-
}uju na to da je interakcija ispitivanih lijekova s D2/5-HT1A receptorima uklju~ena u ni-
sku incidenciju ekstrapiramidalnih nuspojava. Razmatrana je uloga 5-HT1A receptora u
terapiji {izofrenije.
Klju~ne rije~i: atipi~ni antipsihotici, dopaminski D2 receptori, ekstrapiramidalne nuspojave, seroto-
ninski1A receptori, {izofrenija
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